About Progenics
Progenics is a Healthcare company based in United States founded in 1988, and was acquired by Lantheus in October 2019. Imaging compounds targeted radiotherapies to detect and treat prostate cancer. The company has 53 employees. Progenics has completed 3 acquisitions, including AZEDRA, EXINI Diagnostics and Molecular Insight Pharmaceuticals. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Prostate Cancer. Its legal entity is PROGENICS PHARMACEUTICALS, INC. Its competitors include ImaginAb, MDxHealth and GenomeDx Biosciences; 2 of its 3 listed competitors have raised funding.
Company details
Progenics Pharmaceuticals was founded in 1988 in the United States and operates in the oncology sector of pharmaceuticals. Imaging agents and targeted radiotherapeutics are developed, focusing on prostate-specific membrane antigen (PSMA)-targeted technologies for prostate cancer, including antibody drug conjugates and small molecule agents. Additional pipeline assets include Azedra for malignant pheochromocytoma and paraganglioma treatment. The first commercial product, Relistor, is approved for opioid-induced constipation.
- Headquarters United States
- Employees 53
- Stage Public
- SectorsHealthcare
- Website progenics.com
- Social LinkedIn X
- Acquired by Lantheus (Oct 2019)
- Legal Name Progenics Pharmaceuticals, Inc.
Funding Insights of Progenics
- Total Rounds 8
- Last Round Post-IPO — $12.92M
- First Round $15.78M
(Jan 2006)
- Investors Count 1
All 8 funding rounds of Progenics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Progenics
Progenics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Lantheus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer of diagnostic imaging agents and targeted therapeutics | 2008 | lantheus.com | Billerica, United States |
Investor details for Progenics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Progenics
12 people are tracked at Progenics (7 in leadership, 5 in team); the tracked headcount is 53.
| Name | Role | Group |
|---|---|---|
Asha Das | Chief Medical Officer | Leadership |
David W. Mims | Intermin CEO | Leadership |
Vivien Wong | Executive Vice President, Development | Leadership |
Gina Fagan | Senior Director, Medical Information, Drug Safety and Pharmacovigilance Operations | Leadership |
David Myl | Director, Clinical Operations | Leadership |
Terri Parasida | Regional Business Director | Leadership |
Hector Robertson | Associate Director Data Management at Progenics Pharmaceuticals, Inc. | Leadership |
Catherine Paulic | QA Manager | Team |
Linda D. Silberlicht | Clinical Research / Operations | Team |
Jason Perez | Manager, Lab operations | Team |
Edens lamarre | Lab Instrumentation Technician | Team |
Zufan Tsegai | Clinical Project Associate/TMF Specialist | Team |
Complete people profiles for Progenics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Progenics
Progenics has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include AZEDRA, EXINI Diagnostics and Molecular Insight Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapy for pheochromocytoma and paraganglioma diseases is provided. | azedra.com | 2006 | Feb 2019 | $8M | ||
Artificial neural networks are applied to medical scan diagnostics. | exini.com | Lund, Sweden | 1999 | Oct 2015 | $7M | |
Radiopharmaceuticals and molecular imaging agents for use in oncology | molecularinsight.com | Cambridge, United States | 1997 | Jan 2013 | •••• |
Complete acquisition details for Progenics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Progenics
8 dated milestones of Progenics across 31 years, from founding to its latest funding, stage changes and deals.
- Founded Progenics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $15.8M.
- Funding Latest funding round, Post-IPO, of $12.9M.
- Acquisition Acquires Molecular Insight Pharmaceuticals.
- Acquisition Acquires EXINI Diagnostics.
- Acquisition Acquires AZEDRA.
- Exit Acquired by Lantheus.
Competitors of Progenics
Progenics has 3 listed competitors in our database, 2 of them funded. They include ImaginAb, MDxHealth and GenomeDx Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| imaginab.com | 2007 | Los Angeles, United States | $59.64M | 17 | ImaginAb is focused on developing advanced immuno-oncology imaging technologies. | |
| mdxhealth.com | 2003 | Irvine, United States | 174 | Epigenetic tests for personalized cancer assessment and treatment. | ||
| genomedx.com | 2008 | San Diego, United States | $69.75M | 159 | Genomic tests for urologic cancers are developed and commercialized. |
Detailed competitors of Progenics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Progenics
Websites that share an audience with Progenics (progenics.com).
Websites whose visitors overlap most with Progenics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| amylin.com | 100% | View details | |||
| hgsi.com | 89% | View details | |||
| pharming.com | 89% | 16.8K | #1,623,426 | View details | |
| afnm.com | 89% | View details | |||
| shanthabiotech.com | 89% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 23 similar websites and full traffic analytics for Progenics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 23 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Imaging Diagnostics
3 companies that operate in the same segment as Progenics (Imaging Diagnostics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Handheld ultrasound devices are developed for whole-body medical imaging. | 2011 | Guilford, Connecticut, United States | USD 350 M | USD 97.61 M | 464 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 | ||
Ultrasound images are analyzed via AI-based software provided by Exo. | 2015 | Redwood City, California, United States | USD 463.39 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Progenics
Complete news archive for Progenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Progenics
Progenics was founded in 1988 and raised its 1st funding round 18 years after it was founded.
Progenics is headquartered in United States.
Progenics has 53 employees.
Progenics Pharmaceuticals was founded in 1988 in the United States and operates in the oncology sector of pharmaceuticals. Imaging agents and targeted radiotherapeutics are developed, focusing on prostate-specific membrane antigen (PSMA)-targeted technologies for prostate cancer, including antibody drug conjugates and small molecule agents. Additional pipeline assets include Azedra for malignant pheochromocytoma and paraganglioma treatment. The first commercial product, Relistor, is approved for opioid-induced constipation.
Progenics's top competitors include ImaginAb, MDxHealth and GenomeDx Biosciences.
Progenics has made 3 acquisitions, including AZEDRA, EXINI Diagnostics, and Molecular Insight Pharmaceuticals.
Progenics operates through Progenics Pharmaceuticals, Inc..
Yes. Progenics was acquired by Lantheus in October 2019.